Indolent Lymphoma

[Alejandro-Querales-MD]

This article has been medically reviewed by Alejandro Querales, MD — 2022-12-20

Who are the top experts researching treatments for indolent lymphoma?

The top experts researching indolent lymphoma are: Robert O. Dillman, Meng Ji and Jan A Walewski.

What are the top concepts researched in studies about indolent lymphoma?

The most researched concepts in studies of indolent lymphoma are: Relapsed Refractory, Marginal Zone, Response Rate, Free Survival, Phase Trial, Advisory Committees, Entitys Board, Speakers Bureau, Bone Marrow and Myeloid Leukemia.

What are some of the top places that specialize in indolent lymphoma?

Recommended institutions that specialize in indolent lymphoma:

GBMC Center for Rehabilitation Medicine 6701 MD-139 #4377, Towson, MD 21204 Phone: +14438496210

International Foundation of Lymphology 11075 State St STE 35, Sandy, UT 84070 Phone: +18019901990

CCLF 283 Milton Rd, Cambridge CB4 1XQ, United Kingdom Phone: +441223566166

Mark Schaverien 1515 Holcombe Blvd, Houston, TX 77030 Phone: +17137922121

Indolent Lymphoma

[Alejandro-Querales-MD]

This article has been medically reviewed by Alejandro Querales, MD — 2022-12-20

#1	Richard I Fisher
Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia. | Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer ... Southwest Oncology | Cell Lymphoma | Monoclonal Antibodies | Diffuse Large | Chop Chemotherapy

#2	Julie Marie Vose
University of Nebraska Medical Center | Division of Hematology/Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA | Division of ... Cell Lymphoma | Diffuse Large | Bone Marrow | Advisory Committees | Autologous Transplantation

#3	Sandra J Horning
Department of Medicine, Stanford University, Stanford, CA, USA | Sandra J. Horning is the Chief Medical Officer and Global Head of Product Development at Genentech and Roche, ... Follicular Lymphoma | Maintenance Rituximab | Monoclonal Antibodies | Hodgkin Disease | Large Cell

#4	Anton Hagenbeek
Cancer Center Amsterdam, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, The Netherlands; | Department of Hematology, Amsterdam University ... Bone Marrow | Follicular Lymphoma | Rat Model | Leukemic Cells | Maintenance Treatment

#5	James Olen Armitage
From the Department of Emergency Medicine and the New Mexico Poison and Drug Information Center, University of New Mexico Health Sciences Center, Albuquerque (S.A.S.); the ... Cell Lymphoma | Bone Marrow | Complete Remission | Autologous Transplantation | United States

#6	Fernando F Cabanillas
University of Puerto Rico School of Medicine and Auxilio Mutuo Hospital. | Auxilio Mutuo Cancer Center, San Juan, PR | Auxilio Cancer Center, Auxilio Mutuo Hospital, San Juan, ... Cell Lymphoma | Molecular Response | Late Relapse | Hodgkin Disease | Ann Arbor

#7	Peter W McLaughlin
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA | Department of Lymphoma and Myeloma, The University of Texas MD ... Follicular Lymphoma | Molecular Response | Monoclonal Antibodies | Bone Marrow | Ibritumomab Tiuxetan

#8	Hervé Tilly
Centre Henri-Becquerel, Rouen, France | INSERM U1245, Centre Henri Becquerel, University of Rouen, Rouen, France. | Department of Hematology, Centre Henri Becquerel, Rouen, ... Follicular Lymphoma | Diffuse Large | Elderly Patients | Polatuzumab Vedotin | Rituximab Maintenance

#9	Wolfgang D Hiddemann
Department of Medicine III, Ludwig-Maximilians-University Hospital Munich, Germany | University of Munich, Munich, Germany. | Ervaccine Technologies, Centre Leon Bérard, Lyon, ... Acute Myeloid Leukemia | Follicular Lymphoma | Bone Marrow | Situ Hybridization | Complete Remission

#10	Pier Luigi Luigi Zinzani
IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli”, Bologna, Italy; | IRCCS Azienda Ospedaliero, Universitaria di Bologna, Istituto di ... Cell Lymphoma | Brentuximab Vedotin | Seattle Genetics | Italian Society

#11	Martin H Dreyling
Department of Medicine III, LMU Hospital, Munich, Germany | Klinikum der Universität München, LMU, Munich, Germany; | Department of Internal Medicine III, Ludwig‐Maximilians ... Mantle Cell Lymphoma | Rituximab Maintenance | European Mcl Network | Monoclonal Antibodies | Stem Cell

#12	Gilles Andre Salles
Memorial Sloan Kettering Cancer Center, New York | Memorial Sloan Kettering Cancer Center, New York, NY; | Centre Hospitalier Lyon-Sud, Lyon, France; | Department of Medicine, ... Follicular Lymphoma | Large Bcell | Rituximab Maintenance | Polatuzumab Vedotin | Stem Cell

#13	Fredrick B Hagemeister
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. | Department of Lymphoma and Myeloma, University of Texas MD Anderson ... Cell Lymphoma | Hodgkin Disease | Late Relapse | Molecular Response | Diffuse Large

#14	GrilloLopez Grillo‐López
agrillo1@aol.com | PO Box 3797, Rancho Santa Fé, CA 92067, USA. agrillo1@aol.com | National Institute of Child Health and Human Development, National Institutes of Health, ... Monoclonal Antibodies | Follicular Lymphoma | Ibritumomab Tiuxetan | Murinederived Antigens | Chop Chemotherapy

#15	Norbert Schmitz
Department of Population-Based Medicine, Institute of Health Sciences, University Hospital Tuebingen, Tuebingen, Germany | University Hospital Muenster. | Department of ... Depressive Symptoms | Cell Transplantation | Type 2 Diabetes | Mental Disorders | Bone Marrow

#16	Leo I Gordon
Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, United States of America | Division of Hematology/Oncology, ... Cell Lymphoma | Ibritumomab Tiuxetan | Hematologic Malignancies | Monoclonal Antibodies | Brentuximab Vedotin

#17	Jonathan W Friedberg
James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY | University of Rochester Medical Center, Rochester, NY; | James P. Wilmot Cancer ... Follicular Lymphoma | Brentuximab Vedotin | Monoclonal Antibodies | United States | Seattle Genetics

#18	Michael Unterhalt
University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany | Department of Medicine III, University Hospital, Ludwig Maximilian University of Munich, ... Follicular Lymphoma | European Mcl Network | Treatment Failure | Mantle Cell | Advanced Stage

#19	Brian K Link
University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA; | Department of Medicine, University of Iowa, Iowa City, IA, USA. | Department of ... Follicular Lymphoma | United States | National Lymphocare Study | Large Bcell | Monoclonal Antibodies

#20	Jorge Enrique E Romaguera
Department of Lymphoma & Myeloma, MD Anderson Cancer Center, Houston, TX, USA | Department of Lymphoma and myeloma, The University of Texas MD Anderson Cancer Center, Houston, ... Cell Lymphoma | Molecular Response | Cd20 Expression | Monoclonal Antibodies | Denileukin Diftitox

[Alejandro-Querales-MD]

This article has been medically reviewed by Alejandro Querales, MD — 2022-12-20

Moderate Increase Of Secondary Hematologic Malignancies After Myeloablative...

.. in indolent lymphoma.

PATIENTS AND METHODS: Between 1996 and 2002, 440 patients with indolent lymphoma were randomly assigned after a cyclophosphamide, doxorubici

Indolent Lymphoma | Cell Transplantation | Autologous Stem | Asct Patients | Hematologic Malignancies

Fludarabine, Mitoxantrone, Dexamethasone (Fnd) Compared With An Alternating...

.. IV indolent lymphoma ranges from watchful waiting to intensive chemotherapy and stem cell transplantation. In this trial we compared 2 induction regimens followed by 1 year of interferon ...

Indolent Lymphoma | Dexamethasone Fnd | Fludarabine Mitoxantrone | 1 Year | Remission Rates

Investigation Of Fdg-Pet/ct Imaging To Guide Biopsies In The Detection Of...

.. of indolent lymphoma is a dramatic event that occurs in 5-10% of the patients and carries a dismal prognosis.4,5 Previous studies prove that indolent lymphoma entities show a lower FDG ...

Indolent Lymphoma | Histological Transformation | Dramatic Event | Fdg Pet | Emission Tomography

Treatment Of Indolent Lymphoma With Fludarabine/mitoxantrone Combination: A Phase Ii Trial

.. advanced indolent lymphoma (age range: 30-77 years) were treated, using a combination of fludarabine and mitoxantrone, without corticosteroids. Fludarabine was given at 25 mg/m2 for three ...

Indolent Lymphoma | Fludarabine Mitoxantrone | Lymphocytic Chronic | Humans Leukemia | Objective Response

Management Of Indolent Lymphoma: Where Are We Now And Where Are We Going

Indolent lymphoma comprises a unique and challenging subset of non-Hodgkin lymphoma (NHL). While definitions of indolence will vary, the most common indolent NHL subtypes include follicular ...

Indolent Lymphoma | Prolonged Natural | Response Rates | Antineoplastic Agents | Cell Transplantation

How I Treat Indolent Lymphoma

.. with indolent lymphoma, with patients continuing to have an unremitting course of relapse of disease. There appears to have been a change in the natural history of these diseases with the ...

Indolent Lymphoma | Treatment Approaches | Publication Antibodies | Ongoing Clinical Trials | Antineoplastic Agents

Treatment Of Indolent Lymphoma In Germany - Results Of A Representative...

.. advanced-stage indolent lymphoma, therapeutic approaches may vary from watch and wait, antibody monotherapy, immunochemotherapy, or dose-intensified consolidation up to allogeneic ...

Indolent Lymphoma | Treatment Strategies | Cell Transplantation | Antineoplastic Agents | Female Germany

Six Of 12 Relapsed Or Refractory Indolent Lymphoma Patients Treated 10 Years Ago...

.. relapsed indolent lymphoma patients remain disease-free a mean of 9.8 y (range, 8.6-10.7 y) after radioimmunotherapy. Three of 4 transformed lymphoma patients progressed after ...

Indolent Lymphoma | Monoclonal Antigens | Rituximab Treatment | Aged Neoplasm | Hodgkin Male

Nonablative Allogeneic Hematopoietic Transplantation As Adoptive Immunotherapy...

This study investigated the use of a nonablative conditioning regimen to decrease toxicity and achieve engraftment of an allogeneic blood stem cell transplant, allowing a ...

Indolent Lymphoma | Adoptive Immunotherapy | Monoclonal Antibodies | Allogeneic Hematopoietic | Low Incidence

High Ten‐year Remission Rates Following Rituximab, Fludarabine, Mitoxantrone And...

.. untreated indolent lymphoma, enrolled between 1997 and 2002. Patients were randomized to 6-8 cycles of FND followed by 6 monthly doses of rituximab or 6 doses of rituximab given ...

Indolent Lymphoma | Advanced Stage | Partial Response | 68 Cycles | Aged Mitoxantrone

Chemotherapy-Free Initial Treatment Of Advanced Indolent Lymphoma Has Durable...

.. For indolent lymphoma, the optimal timing, sequence, and choice of therapeutic regimens remain a matter of debate. In two Nordic Lymphoma Group randomized trials, symptomatic or clearly ...

Indolent Lymphoma | 10 Years | New Therapies | Rituximab Chemotherapy | Firstline Therapy

Indolent Lymphoma With Composite Histology And Simultaneous Transformation At...

.. transformed indolent lymphomas, the clinicopathological features of indolent lymphoma and simultaneous secondary transformation upon initial diagnosis (ssDLBCL) are insufficiently ...

Indolent Lymphoma | Diffuse Large | Germinal Center | Dlbcl | Trend

Pi3kδ Inhibition By Idelalisib In Patients With Relapsed Indolent Lymphoma

BACKGROUND: Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B ...

Indolent Lymphoma | Idelalisib Patients | Antitumor Activity | Median Duration Response | Prior Therapies

Phosphatidylinositol 3-Kinase Inhibition By Copanlisib In Relapsed Or Refractory...

.. with indolent lymphoma. Patients and Methods In this phase II study, 142 patients with relapsed or refractory indolent lymphoma after two or more lines of therapy were enrolled to receive ...

Indolent Lymphoma | Phosphatidylinositol 3 | Objective Response Rate | Kinase Inhibition | Median Duration Response

High Serum Interleukin-6 Levels Correlate With A Shorter Failure-Free Survival In...

Interleukin-6 (IL-6) is a potent immunomodulatory cytokine that may have pathogenetic and prognostic significance in a number of disorders. The objective of this study was to examine the ...

Indolent Lymphoma | Serum Il6 | Phenotypic Characteristics | Interleukin6 Levels | Patients Elevated

[18f]‐fdg Pet/ct In The Staging And Management Of Indolent Lymphoma: A...

.. stage indolent lymphoma being considered for curative radiation therapy.

METHODS: We conducted a prospective multicenter registry study that included 197 patients accrued between May 1, ...

Indolent Lymphoma | Pet Staging | Management Patients | Stage Iii | Active Treatment

High-Dose Therapy For Indolent Lymphoma

Stem-cell transplantation (SCT) has become the treatment of choice for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL). However, the role of SCT in the management of patients ...

Indolent Lymphoma | Dose Therapy | Cell Transplantation | Hematopoietic Stem | Topic Combined

4 Gy Versus 24 Gy Radiotherapy For Patients With Indolent Lymphoma (Fort): A...

BACKGROUND: Follicular lymphoma has been shown to be highly radiosensitive with responses to doses as low as 4 Gy in two fractions. This trial was designed to explore the dose response for ...

4 24 | Indolent Lymphoma | Local Progression | 12 Fractions | Radiotherapy Patients

Retrospective Analysis Of Stage I And Ii Indolent Lymphomas At The National...

.. II indolent lymphoma treated at the National Cancer Institute between January 1958 and December 1984. Patients were treated by a variety of approaches, with 48/54 patients receiving some ...

Indolent Lymphoma | Radiation Therapy | Retrospective Analysis | Primary Treatment | 10 Years

Bendamustine Mitoxantrone And Rituximab (Bmr): A New Effective Regimen For...

.. refractory indolent lymphomas. The anti-CD20 monoclonal antibody rituximab (R) has produced an overall response rate (ORR) of 50% as a single agent in relapsed or refractory indolent ...

Bendamustine Mitoxantrone | Indolent Lymphoma | Monoclonal Antibodies | Patients Relapsed | Rituximab Bmr